Fingolimod Completed Phase 4 Trials for Relapsing Multiple Sclerosis (RMS) Basic Science

IndicationsStatusPurposePhase
CompletedBasic Science4
clinicaltrials.gov IdentifierTitleDrugs
NCT03257358A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod